Brief: Epigenomics Plans Capital Reduction And To Issue Convertible Bonds

Epigenomics AG

03/11/2020 10:52

Nov 3 (Reuters) - EPIGENOMICS AG  ECXn.DE :
    * EPIGENOMICS AG: CAPITAL REDUCTION AND FURTHER
AUTHORIZATION TO
ISSUE CONVERTIBLE BONDS WITH BACKSTOP INVESTOR PLANNED
    * CAPITAL REDUCTION IS TO TAKE PLACE IN TWO STEPS
    * FIRST, SHARE CAPITAL SHALL BE REDUCED BY EUR 6.00 FROM EUR
47,129,846.00 TO EUR 47,129,840.00 BY WITHDRAWING SIX TREASURY
SHARES ACQUIRED FREE OF CHARGE
    * ORDINARY CAPITAL REDUCTION SHALL BE CARRIED OUT BY
COMBINING
SHARES OF COMPANY IN RATIO 8:1
    * SECONDLY, SHARE CAPITAL OF COMPANY SHALL BE REDUCED BY
MEANS OF
AN ORDINARY CAPITAL REDUCTION BY EUR 41,238,610.00 FROM EUR
47,129,840.00 TO EUR 5,891,230.00
    * NEW AUTHORIZATION TO ISSUE CONVERTIBLE BONDS WITH A
NOMINAL
VALUE OF UP TO EUR 5.5 MILLION, WHICH IS ALSO TO BE PROPOSED TO
EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING, SHALL BE LIMITED
UNTIL MARCH 31, 2021
    * ORDINARY CAPITAL REDUCTION SERVES PARTLY TO COVER LOSSES
AND
PARTLY TO ALLOCATE TO COMPANY'S CAPITAL RESERVES
    * CONVERSION PRICE PER NO-PAR VALUE SHARE OF COMPANY AMOUNTS
TO
EUR 1.10
    * CONVERSION RIGHTS AND OBLIGATIONS CAN ACCORDINGLY BE
ESTABLISHED
FOR UP TO 5,000,000 NEW NO-PAR VALUE SHARES OF COMPANY

Source text for Eikon:  ID:nEQ9qqxkba 
Further company coverage:  ECXn.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))